| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 11/6/268:15 AM | -$0.82 | -$0.64GAAP | +22.0% | -12% | $0.64M | $1.60M | +149% | -4% | |
| Q2 '26 | 8/6/268:15 AM | -$0.65 | -$0.90GAAP | -38.5% | -67% | $0.83M | $1.16M | +39.1% | — | |
| Q1 '26 | 5/8/268:30 AM | -$0.55 | -$0.71GAAP | -29.1% | -58% | $0.51M | $1.08M | +111% | ⚠ Check | |
| Q4 '25 | 2/27/268:30 AM | -$0.59 | -$0.51GAAP | +13.6% | -11% | $1.64M | $2.32M | +41.5% | +409% | |
| Q3 '25 | 11/14/258:00 AM | -$0.56 | -$0.57GAAP | -1.8% | -90% | $0.18M | $1.67M | ⚠ Check | ⚠ Check | |
| Q2 '25 | 8/8/258:00 AM | -$0.46 | -$0.54GAAP | -17.4% | -93% | $0.20M | $0 | ⚠ Check | ⚠ Check | |
| Q1 '25 | 5/13/258:00 AM | -$0.28 | -$0.45GAAP | -60.7% | -25% | $0.14M | $0.05M | ⚠ Check | ⚠ Check |
⚠ Potential error in calculation, check manually. The two revenue figures may be in different units or currencies. Reported revenue shows as zero, which usually means the figure is missing.
GAAP = diluted EPS as filed with the SEC.